fda glp-1 warning letters october 2025 CDER Jump 50% in FY — What That Means for Industry FDA Issues Warning Letters to

GLP-1 agonists are most often used by people with type 2 diabetes to manage blood sugar levels, but in recent years, theyve become a top treatment choice for people with overweight or obesity for weight management

Continuous Expansion of Research and Application Scenarios At present, its application has been extended to fields such as cellular antiaging and neuroprotection

Premium Product Concepts Pre-/post-workout antioxidant formulas: Powered by liposomal glutathione to buffer oxidative stress from training

It brings branched chain amino acids (BCAA), minerals, vit

The benefits of strength training and physical labor must be balanced with the risk of injury, particularly in older adults